{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:06:07Z","timestamp":1787889967121,"version":"build-2784847793"},"reference-count":40,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Capital Clinical Diagnosis and Treatment Technology Research and Transformation Application","award":["Z211100002921059"],"award-info":[{"award-number":["Z211100002921059"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>To evaluate the prediction model comprised of patients\u2019 laboratory results and single-nucleotide polymorphism (SNP) markers of host gene for the clearance of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB) who underwent interferon (IFN)-\u03b1 therapy, this prospective case\u2013control study enrolled 131 patients with CHB who underwent IFN-\u03b1-based regimens in our hospital between January 2015 and September 2019. Among them, 56 cases were without HBsAg clearance, while the other 75 cases had HBsAg clearance. Multivariable logistic regression analysis showed that CYP27B1 rs4646536 (odd ratio [OR] = 0.155, 95% CI: 0.030\u20130.807, p = 0.027), PAK4 rs9676717 (OR = 11.237, 95% CI: 1.768\u201371.409, p = 0.010), IL28B rs12979860 (OR = 0.059, 95% CI: 0.006\u20130.604, p = 0.017), baseline HBsAg (OR = 0.170, 95% CI: 0.040\u20130.716, p = 0.016), and HBeAg status (OR = 3.971, 95% CI: 1.138\u201313.859, p = 0.031) were independently associated with HBsAg clearance. The model that included rs3077, rs4646536, rs9676717, rs2850015, rs12979860, baseline HBsAg, HBeAg status, and HBV DNA had the best prediction performance for HBsAg clearance prediction, with AUC = 0.877, 80% sensitivity, and 81% specificity. In conclusion, laboratory results and gene polymorphisms before treatment might have a good predictive value for HbsAg clearance after IFN-\u03b1 treatment in CHB.<\/jats:p>","DOI":"10.3390\/diagnostics14010118","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T05:23:30Z","timestamp":1704345810000},"page":"118","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prediction Model for the Clearance of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B before Interferon Therapy: A Prospective Case\u2013Control Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Nan","family":"Geng","sequence":"first","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Ma","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Jin","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Lu","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Chen","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices","volume":"67","author":"Schillie","year":"2018","journal-title":"MMWR Recomm. Rep."},{"key":"ref_2","unstructured":"(2022, February 05). Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021. Accountability for the Global Health Sector Strategies 2016\u20132021: Actions for Impact [EB\/OL]. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/342808\/9789240030985-eng.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Trepo","year":"2014","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.14218\/JCTH.2016.00019","article-title":"Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)","volume":"5","author":"Hou","year":"2017","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/apt.12910","article-title":"Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B","volume":"40","author":"Brouwer","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/gutjnl-2014-308546","article-title":"Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues","volume":"65","author":"Fan","year":"2016","journal-title":"Gut"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1111\/jgh.13414","article-title":"Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B","volume":"31","author":"Zhu","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.gastro.2010.03.059","article-title":"Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B","volume":"139","author":"Reijnders","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S0168-8278(12)60012-9","article-title":"Management of treatment failure in chronic hepatitis B","volume":"56","author":"Zoulim","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"691365","DOI":"10.3389\/fmed.2021.691365","article-title":"Interleukin-28B Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients with Chronic Hepatitis B: A Meta-Analysis","volume":"8","author":"Ying","year":"2021","journal-title":"Front. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/apt.12717","article-title":"Review article: Genetic factors that modify the outcome of viral hepatitis","volume":"39","author":"Stattermayer","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chuaypen, N., Tuyapala, N., Pinjaroen, N., Payungporn, S., and Tangkijvanich, P. (2019). Association of NTCP polymorphisms with clinical outcome of hepatitis B infection in Thai individuals. BMC Med. Genet., 20.","DOI":"10.1186\/s12881-019-0823-x"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1002\/jmv.27880","article-title":"STAT4 genetic polymorphism significantly affected HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving Peginterferon-alpha therapy: A prospective cohort study in China","volume":"94","author":"Qi","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e22367","DOI":"10.1002\/jcla.22367","article-title":"Polymorphisms of CYP27B1 are associated with IFN efficacy in HBeAg-positive patients","volume":"32","author":"Wu","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/hep.1840360618","article-title":"Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study","volume":"36","author":"King","year":"2002","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.antiviral.2011.12.009","article-title":"Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese","volume":"93","author":"Wu","year":"2012","journal-title":"Antiviral Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3851\/IMP1841","article-title":"Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy","volume":"16","author":"Tseng","year":"2011","journal-title":"Antivir. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1089\/jir.2006.0163","article-title":"MxA induction may predict sustained virologic responses of chronic hepatitis B patients with IFN-alpha treatment","volume":"27","author":"Kong","year":"2007","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.meegid.2014.12.011","article-title":"Influence of IL10 gene polymorphisms on the severity of liver fibrosis and susceptibility to liver cirrhosis in HBV\/HCV-infected patients","volume":"30","author":"Guo","year":"2015","journal-title":"Infect. Genet. Evol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection--natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/hep.27323","article-title":"Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections","volume":"61","author":"Rehermann","year":"2015","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/0168-8278(92)90032-K","article-title":"Prevalence of markers of hepatitis viruses in out-patient alcoholics","volume":"15","author":"Laskus","year":"1992","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.3748\/wjg.v12.i30.4788","article-title":"Host susceptibility to persistent hepatitis B virus infection","volume":"12","author":"He","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3389\/fgene.2019.00696","article-title":"Host Genetic Determinants of Hepatitis B Virus Infection","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0204-0","article-title":"PAK4 signaling in health and disease: Defining the PAK4-CREB axis","volume":"51","author":"Won","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3760\/cma.j.issn.0366-6999.20123327","article-title":"Gene polymorphisms of interleukin-28, p21-activated protein kinases 4, and response to interferon-alpha based therapy in Chinese patients with chronic hepatitis B","volume":"126","author":"Yu","year":"2013","journal-title":"Chin. Med. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3389\/fimmu.2017.01661","article-title":"Interferon (IFN)-lambda Takes the Helm: Immunomodulatory Roles of Type III IFNs","volume":"8","author":"Zanoni","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/jvh.12193","article-title":"Relationship between polymorphisms near the IL28B gene and spontaneous HBsAg seroclearance: A systematic review and meta-analysis","volume":"21","author":"Lee","year":"2014","journal-title":"J. Viral Hepat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2011.11.025","article-title":"Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B","volume":"142","author":"Sonneveld","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"615603","DOI":"10.3389\/fimmu.2020.615603","article-title":"Interferon Receptor Trafficking and Signaling: Journey to the Cross Roads","volume":"11","author":"Zanin","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2893.2008.01040.x","article-title":"A non-synonymous single nucleotide polymorphism in IFNAR1 affects susceptibility to chronic hepatitis B virus infection","volume":"16","author":"Zhou","year":"2009","journal-title":"J. Viral Hepat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"a021428","DOI":"10.1101\/cshperspect.a021428","article-title":"Immune Response in Hepatitis B Virus Infection","volume":"5","author":"Tan","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.3389\/fimmu.2019.03127","article-title":"Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection","volume":"10","author":"Meng","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.4049\/jimmunol.1302296","article-title":"Vitamin D receptor and Jak-STAT signaling crosstalk results in calcitriol-mediated increase of hepatocellular response to IFN-alpha","volume":"192","author":"Lange","year":"2014","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3851\/IMP2401","article-title":"Plasma microRNA profile as a predictor of early virological response to interferon treatment in chronic hepatitis B patients","volume":"17","author":"Zhang","year":"2012","journal-title":"Antivir. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijid.2021.05.015","article-title":"Serum microRNAs predict response of patients with chronic hepatitis B to antiviral therapy","volume":"108","author":"Tan","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"784172","DOI":"10.3389\/fmed.2021.784172","article-title":"Suppression of Interferon-alpha Treatment Response by Host Negative Factors in Hepatitis B Virus Infection","volume":"8","author":"Wang","year":"2021","journal-title":"Front. Med."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/1\/118\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:39:58Z","timestamp":1760103598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/1\/118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["diagnostics14010118"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14010118","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]}}}